Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 423 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Botulinum toxin(Botox) Clear all

Conditions: Urgency Urinary Incontinence
Interventions: Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox]; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 5
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 2 more

Conditions: Overactive Bladder
Interventions: Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U; Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Middlebury, Connecticut

Conditions: Benign Essential Blepharospasm, Hemifacial Spasm
Interventions: DaxibotulinumtoxinA; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Glabellar Frown Lines
Interventions: Botulinum Toxin A, Placebo; Drug
Lead sponsor: Croma-Pharma GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 784 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Encino, California • San Francisco, California + 6 more

Conditions: Pancreatic Carcinoma
Interventions: Botulinum Toxin Type A; Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cervical Dystonia
Interventions: daxibotulinumtoxinA for injection; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 37
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 32 more

Conditions: Photoaging, Wrinkle, Sun Damaged Skin
Interventions: Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug); Combination Product
Lead sponsor: Vitality Institute Medical Products; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rancho Mirage, California

Conditions: Cerebral Palsy, Muscle Spasticity
Interventions: Botulinum toxin type A; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Years to 12 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cosmetic Techniques
Interventions: Onabotulinumtoxina for Injection, Abobotulinumtoxina for Injection, IncobotulinumtoxinA for Injection, PrabotulinumtoxinA for Injection; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions: Botulinum-A toxin, Dimethyl sulfoxide (DMSO); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Mood
Interventions: Botulinum Neurotoxin, Placebo; Drug
Lead sponsor: DeNova Research; Other
Eligibility: 10 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pelvic Floor Disorders
Interventions: Botulinum neurotoxin, High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device; Drug · Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Urinary Incontinence, Urinary Bladder, Overactive
Interventions: BOTOX®; Biological
Lead sponsor: Allergan; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 8
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more

Conditions: Glabellar Lines
Interventions: JTM201, Placebo; Biological
Lead sponsor: Jetema USA Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Obesity
Interventions: Botulinum toxin, Overstitch Endoscopic Suturing System; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
Interventions: NT 201, NT 201 Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 27
States / cities: Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more

Conditions: Flexion Contracture Following Total Knee Replacement
Interventions: Botox, placebo; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 2
States / cities: Bryn Mawr, Pennsylvania • Lankenau, Pennsylvania

Conditions: Hyperhidrosis
Interventions: Botulinum Toxin Type A; Biological
Lead sponsor: Allergan; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cerebral Palsy
Interventions: Music Therapy; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 1 Year to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Lower Limb Spasticity
Interventions: Botulinum toxin type A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: Washington D.C., District of Columbia • Miami, Florida • North Palm Beach, Florida + 23 more

Conditions: Upper Limb Spasticity
Interventions: DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo; Biological · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 26
States / cities: Downey, California • Fountain Valley, California • Long Beach, California + 22 more

Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride; Drug
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more

Conditions: Stress Urinary Incontinence
Interventions: onabotulinumtoxin A; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Post-Operative Atrial Fibrillation
Interventions: AGN-151607, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Stanford, California • New Haven, Connecticut • Washington D.C., District of Columbia + 16 more

Search by objective public record fields.

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles

Botulinum Toxin (BOTOX) for Cerebral Palsy

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Botulin-A Toxin Instillations and Overactive Bladder

Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction

Botox for Chronic Pelvic Pain

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Endoscopic Gastric Reduction for Weight Management

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Botulinum Toxin A to Treat Flexion Contracture After Total Knee Arthroplasty

A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis

Music Therapy During Botulinum Injections

Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

Anticholinergic vs. Botox Comparison Study

Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)